

Figure 1. Conceptual scheme for a generic biosensor. The receptor layer can use many biological receptors (enzymes, antibodies, oligonucleotide sequences, aptamers, etc.) or non-biological entities such as molecularly imprinted polymers (MIPs) or various chemical functionalities to increase selectivity. Detectable analytes include: chemical species, nucleic acid sequences and proteins. The transducer element refers to the underlying sensor principle, of which there are many, including: optical, electrochemical, piezoelectric, thermal and electrical sensors. (Online version in colour.)

systems is driven by fundamental advances in a range of disciplines, including microsystems engineering, chemistry (enhanced bio-recognition elements, hydrogel research and new nanoscale technologies) and biomarker discovery.

Biosensor technologies can take many forms but a convenient and generic way to think about a biosensor is presented in figure 1. The sensor must be brought into contact with the sample. The sample can undergo a pre-processing step such as the conversion of blood to serum via centrifugation if required, or unprocessed samples can either be placed on the sensor (*in vitro* diagnostics) or allowed to come directly into contact with the sensor in the natural physiological state as in the case of wearable or implantable devices. Selectivity for the analyte of interest is achieved by employing a 'bio-recognition element' to selectively capture the analyte of interest from the sample. Binding and de-binding of the analyte gives rise to signal changes which can be measured through the sensor's transducer element. There are many governing principles for the method of signal transduction, including, optical, electrochemical, piezoelectric, thermal, magnetic and electrical. Once the signal has been generated it must be turned into an electrical format for display and interpretation.

The biomedical sensing field is a hotbed of innovation with numerous academic and industrial groups working directly on the development of new technologies. The relatively high levels of competition in the field along with the fact that consumers are embracing smart healthcare technologies allied with the economic pressures on healthcare providers and governments are in combination leading to new technologies which are by design low cost, mass manufacturable, durable, 'connected' and simple to use. At the same time, physiological research over the last several decades has showed that wild animals have developed physiological mechanisms with which to cope with some of the greatest problems facing society at present, including obesity [13], hyperglycaemia [14] hypoxia/hypoxaemia [15,16] and viral infection [17], but these have been relatively poorly studied to date owing to a paucity of available technologies. Many new biosensor systems have applicability to the study of physiological status in free living animals

where constant manipulation of the device is not possible and also where long-term power budget, connectivity and durability are important considerations. The fact that devices are becoming more lightweight, less invasive and easier to place is also an important trend. After giving some consideration to existing systems for recording physiological measurements in wild animals, this article will explore recent innovations in the human biomedical sensing on a sub-disciplinary basis, highlighting high quality articles which report useful developments of potential relevance to studying animal physiology and more broadly discusses the prospects for deploying such technologies in wild animal monitoring. The article has chosen to focus on developments disciplines which focus on detection of diseased states in human health. This is because these technologies face the most stringent demands in terms of sensitivity, implantability and power budget and therefore have the most to offer in terms of measuring ill health and disease among animal populations as well as monitoring animals in normal health. Developments in human wearable devices are well covered elsewhere and are signposted in the section below which makes a brief commentary on wearable devices and smart textiles. Finally, the article introduces the idea of extrapolating the measurement of human biomarkers into animal population using cutting edge technologies. This is important because many of the current wearable technologies do not have the ability to measure beyond simple biomarkers (blood glucose, lactate, O_2) meaning that some of the technologies highlighted raise the potential for monitoring real time biomarker changes in animals, *in vivo*, at $ng\ ml^{-1}$ and $pg\ ml^{-1}$ levels—something outside the limits of current wearable solutions.

2. Examples of current technologies used in wild animal monitoring

The range of measurements available and the underlying principles of animal monitoring technology have been well reviewed recently [18]. Wild animal tracking is a vibrant and mature field and it is clear that established technologies allow the measurement of several important parameters, including many characteristics of animal performance such as speed [19], acceleration and motion [20], stroke rate/venous oxygenation during diving [21] and soaring height [22] which are measured with ease. Physiological, biochemical and environmental parameters such as dissolved oxygen [23], heart rate [24], EEG [25] and gastric pH [26] are also measurable with current devices and provide valuable information on important aspects of animal physiology and the nature of the environment in which they live. Consideration has also been given to effective blood glucose monitoring in populations of grey seals [27]. These are a very small subset of published studies with similar works existing for a wide range of parameters and sensor types [18]. As with humans the main challenge for next generation sensing is reliably accessing the biochemical realm with easily deployed, 'smart' devices with useful measurement lifetimes. In the face of climate change, increased interactions with human societies and disease outbreaks it will be ever more important to be able to measure the biochemical, physiological and pathological status of wild and captive animals. One very pertinent example is the outbreak of a mutated strain of

127 SARS-CoV-2 in mink in Denmark¹ and the requirement to
 128 track pathogen spread quickly within an animal population.
 129 A highly intriguing possibility is the development of such
 130 ‘SMART’, low cost, easy to deploy and robust sensors to
 131 allow animals living freely in the environment to be used
 132 as a network of sensors for environmental change, pathogen
 133 emergence & spread and as a proxy for certain aspects of
 134 human activity—this area has been recently well reviewed
 135 [28]. The following sections of this review will outline
 136 recent advances in engineering, chemistry and biomolecular
 137 science specifically for medical devices and suggest how
 138 and where these can potentially be applied to measurements
 139 in wild animals. This article is not intended to be an exhaus-
 140 tive review of established monitoring technologies in wild
 141 animals, its aim is to highlight cutting-edge advances in
 142 chemistry, microsystems engineering and nanoscience, par-
 143 ticularly those arising from human medical applications
 144 and point out how in the future they might be developed
 145 for use in wild animals.

147 3. Developments in microsystems engineering 148 and implantable devices

149 Modern biosensor technologies are often underpinned by
 150 cutting edge engineering. To understand how such devices
 151 operate and might be applied to the measurement of physio-
 152 logical status in wild animals it is necessary to understand the
 153 production techniques employed, key design features and the
 154 relative advantages these approaches confer upon the final
 155 device and its performance. Due to the fact that our focus
 156 is on measurement in wild animals, engineering themes
 157 which are applicable to this area have been selected for
 158 further elaboration.

159 Microsystems engineering is a key area which underpins
 160 many modern biosensor technologies. The area is more often
 161 referred to as ‘Microelectromechanical systems’ (MEMS) and
 162 commonly refers to devices on the scale of 1–100 μm with
 163 smaller devices referred to as ‘Nanoelectromechanical Systems’
 164 (NEMS). Effective biosensing strategies and investigations into
 165 the enhanced analytical performance of ‘small’ electrode sen-
 166 sors have been demonstrated with micro [29] and nanoscale
 167 electrodes [30]. These studies have often focussed on *ex vivo*
 168 measurement of a particular gene sequence or protein and so
 169 do not shed much insight into the prospects for long-term
 170 implantation or wearability. A current area in clinical/biomed-
 171 ical engineering where MEMS devices play a key role is
 172 neuroscience and there is a whole sub-discipline dedicated to
 173 the design, fabrication and deployment of neuroprosthetic
 174 devices for real time recording of brain activity [31]. Indeed
 175 perhaps the most sophisticated physiological devices in use
 176 in wild animals so far is also in this discipline, with small log-
 177 gers recording brain activity in several species of free flying
 178 birds [32], tackling research questions concerning navigation
 179 [33] and sleep [34]. A strong theme at present driving much
 180 innovation is the field of ‘optogenetics’ where optical stimu-
 181 lations in combination with genetic manipulation of neural
 182 circuits are used to modulate neuronal activity which is then
 183 subsequently recorded using microelectrodes or microelec-
 184 trode arrays [35]. The ability to specifically modify neuronal
 185 circuits and modulate their activity has provided great insight
 186 into brain structure and function. Additionally, the area is seen
 187 as a promising route towards the treatment of conditions such
 188 as epilepsy and Parkinson’s disease. Recent work in this area
 189

has seen the combination of optogenetic modulation of neu-
 ron circuitry coupled with dopamine detection using a
 microfabricated device bearing a micro LED and a thin film
 PEDOT working electrode [36]. The reported device was
 implanted into free living mice and used to modulate and
 record neurotransmitter release. An elegant aspect of this
 study is the selective measurement of a neurotransmitter in
 combination with neuronal activity and optogenetic manipu-
 lation. The use of MEMS based systems to achieve neuro-
 optogenetic modulation along with targeted refillable drug
 release has also been demonstrated in an impressive study
 showing realization of an injectable device with on board
 drug delivery for optogenetic stimulation and combined
 drug release [37], which opens up potential for simultaneous
 stimulation and release in wild animal populations. A recently
 reported system called ‘SiNAPS’ [38] is featured in figure 2
 and is a multi-channel single shaft neuroprosthetic device
 capable of recording neuronal activity in highly localized
 regions of the brain with exceptionally high spatial and tem-
 poral resolution. Through a new and innovative design, the
 technology overcomes previous challenges of making simul-
 taneous multi-channel neuronal recordings without
 expanding the size of the chip. Neuroprosthetic devices such
 as those mentioned above have tremendous applicability to
 the measurement of physiology in wild animals, the ability
 to track neuronal activity in brain circuits has largely been
 restricted to laboratory-based investigations but with develop-
 ments such as these the possibility of long-term neurological
 monitoring and even neurological manipulation in wild ani-
 mals is coming closer. Indeed such technology would not
 allow description of the neuronal activity of wild animals at
 liberty e.g. during flying and diving [39,40] but also to
 reveal and even mechanistically isolate the neural factors
 that pre-dispose wild animals to stressors such as capture
 and handling for study, and anthropogenic light [32].

Electrochemical biosensors rely on the use of a potentio-
 stat to measure currents and voltages at the biosensor
 electrodes under test. Traditionally, the potentiostat has
 tended to be a laboratory-based instrument, often large in
 size and inflexible in terms of its measurement options. In
 recent years, there has been a large amount of research on
 portable, low cost instruments with a strong emphasis on
 instruments which can be assembled for <\$100 for in field
 testing and also on the development of potentiostats using
 integrated circuits for implantable detection purposes. The
 DSTaT [41] and PSoC-Stat [42] instruments were both devel-
 oped in an open source manner using off the shelf
 components and bespoke graphical user interfaces and
 using both voltammetric and amperometric measurements
 were employed to detect the potassium ferri-ferro cyanide
 redox couple and citric acid, glucose and lead, respectively.
 Another device, the SimpleStat was developed at cost of
 approximately £5 per unit and was used to detect the oxacil-
 lin resistance gene from bacterial samples [43]. Low cost
 potentiostatic systems are likely to drive the adoption of
 simple in the field measurements which for example might
 allow the detection of drug resistant bacteria or potentially
 zoonotic infections among groups of wild animals. With
 this in mind, consideration has been given specifically to
 the requirements of any potentiostat dedicated to probing
 the properties of bacterial samples [44]. Finally, on the topic
 of low cost electrochemical platforms, the iMED device




Figure 2. Architecture of the SiNAPS probe and of the recording system. (a) Implantable CMOS probes with dense electrode arrays can record broad-band bioelectrical signals across brain circuits with sub-millisecond and single-neurons resolutions. (b) Comparison of the integration potential of simultaneously recording electrodes (i.e. channels) per total silicon area (i.e. shaft and base of the probe) for different architectures proposed in the literature. SiNAPS probes achieve a number of effectively recording channels per unit of silicon area that is one order of magnitude larger than other presently available CMOS architectures and the NeuroPixels. Schematics of the circuit architecture for (c) the SiNAPS probe and (d) its acquisition system providing simultaneous neural recordings from the entire electrode array. Each electrode-pixel features an electrode and a small area DC-coupled in-pixel circuit for local amplification and low-pass filtering. A probe integrates multiple instances of the same low-area and low-power analogue front-end module of 32 electrode-pixels that are read out in a time-division multiplexed fashion. The on-probe digital control unit (DCU) provides the timing signals required for correct circuit operation and implements a bidirectional serial peripheral interface (SPI) for device configuration. An FPGA-based acquisition unit generates timing signals for the ADCs and provides a camera link standard connection with a PC for data storage and online visualization [38]. (Online version in colour.)

shows promise as a combined potentiostat with microfluidic and electrochemical components, already achieving reliable glucose detection [45]. To progress beyond low cost external circuitry and realize implanted electrochemical measurements it is necessary to develop potentiostatic circuits which can be miniaturised onto a MEMS device. Research groups have addressed this area of need and on board potentiostats have been developed. One example involves design, simulation and example measurements from a low power implantable potentiostat system [46]. Other implantable potentiostat systems are featured in the literature, very often as part of a fully implanted probe system and so other examples will be featured in later sections.

In addition to the on board circuitry, it is important to provide power to the biomedical sensor and if necessary the option to recharge implantable devices, particularly those intended for long-term use. Powering of medical devices is a subfield of its own with consideration given to overall power budgets of devices across their useful lifetime and the development of novel batteries and powering schemes for specific use in medical technologies. An important consideration in this area are the regulations around powering of medical devices and in particular, safety limits which are often established by national regulators. Examples of studies which give consideration to power include: design and testing of a far field based RF powering systems for implantable devices where wireless

power transfer was shown as feasible using a frequency of 403 Hz at a working distance of 17 cm, the development of an algorithm to ensure optimum power consumption and effective recharging for a network of body area sensors [47] and finally a study which elegantly shows development of a battery and lead less pacemaker where the energy harvested from contraction and relaxation of heart muscle is used to harvest the electrical energy necessary to drive a commercial pacemaker circuit [48]. To realize long-term implantation and therefore devices which can give insight into wild animal behaviour, the question of power supply and power budget is critical. To track migration events or free living animals on a long-term basis, perpetual power with the need for minimal interference from the scientist is most desirable and the application of power sources which harvest energy from movement or blood chemistry (e.g. glucose) stand to contribute significantly to research efforts in this area. Such efforts would help to minimize the size and mass of physiological recording devices on wild animals, which may not only impact movement and survival [49] but also data integrity [50]. Alternatively, RF powering systems could be used to investigate the physiology of wild animals that return to specific locations, such as nests (e.g. seabirds), burrows (e.g. badgers), territories (e.g. lions) or stop over sites during migration (e.g. migrating birds).

The combination of sensor chemistry, measurement circuitry and power options when successfully achieved can give rise to surprisingly effective devices with recent examples including the measurement of oxygen tension in the gastrointestinal tract of rats [51] via the miniaturization of the Clark electrode into an implantable device which can be administered via a needle followed by a demonstration of successful mapping of tumour hypoxia in sheep using the same device [52]. Both of these studies showcase sensitive and responsive measurements of oxygen tension in animals and raise the prospect of monitoring physiological status independently and in an intervention free manner (post implantation). Currently, intravascular oxygen electrodes have been used in penguins, seals and turtles to measure oxygen during diving but are generally limited to several days to a week in recording duration [21]. A critical performance characteristic for implantable devices is efficacy over time. This includes biocompatibility and sensor longevity and there are examples of recent studies which attempt to investigate these phenomena. For example, the PRECISE study [53] studied the behaviour of an implanted glucose monitoring system designed for use over a period of 90 days, finding satisfactory accuracy, no adverse safety events and development of a new algorithm to help adjust for changes in sensor performance over time. The biocompatibility and electrical activity of parylene-platinum-based microelectrode arrays were also evaluated following a twelve week implantation into rats [54]. Again good safety profile was observed with very little signature of inflammation or rejection of the implant in combination with satisfactory electrical performance. Studies like these, which show good biocompatibility, an absence of adverse events and good measurement reliability are demonstrating development of technologies with strong prospects for implantation into wild animals.

4. Developments in wearable devices

Wearable devices are a popular area of research with technologies in this area featuring strongly in the literature. The

definition of a wearable device is incredibly wide and so the discipline spans many technology forms, disease areas and use cases. The diversity of the field means there are a wealth of technologies which could potentially be applied to the challenge of measuring physiological status in animals. A strong area of interest in the wearables area is the diabetes market with several commercially available systems currently available for wearable and continuous monitoring of blood glucose levels. This is a well-researched and burgeoning area of literature with comprehensive and relatively recent review articles for the interested reader [10]. Recent examples of innovative new wearable glucose technologies include a fully autonomous wearable droplet microfluidic device which samples glucose and lactate in dermal tissue using a microdialysis probe in combination with a microfluidic chip [55]. In addition, a highly stretchable and strain insensitive glucose sensor, produced by employing gold fibres to generate a three electrode cell in a woven fabric [56]. The sensor was found to be strain insensitive and following functionalization with Prussian blue and glucose oxidase was able to successfully record glucose levels in sweat. Finally, a nanoporous gold electrode functionalised for detection of glucose was created and deployed on a stretchable three-dimensional micro-patterned polydimethylsiloxane (PDMS) membrane to achieve wearable detection of glucose in sweat [57]. The continuous measurement of blood glucose in wild animals could be extremely informative for understanding fuelling for peak and endurance exercise (e.g. predation events versus migration, [58], as well as how animals manage limited resources in heterogeneous landscapes [59].

Aside from glucose, other wearable sensor systems are becoming more commonly reported in the literature. For example, lactate is an important biomarker molecule, the levels of which can give important information on physiological status. Lactate is an important biomarker of sepsis [60]. A recent study showed the development of a thin, flexible wearable system which could be controlled by near-field communication (NFC) for lactate detection in sweat [12]. The measurement of lactate is of particular interest in understanding the physiology of diving animals, as the accumulation of lactate marks the point at which the 'aerobic dive limit' has been exceeded [61]. Nevertheless, it has important implications for understanding the effects of fisheries by-catch of air breathing species, for understanding how they may be impacted by overfishing of prey stocks and by climate change. Another example of a flexible and in this case stretchable system was the design of a soft, conformable, biocompatible strain sensor based on ultra-thin stretchable electronics for the measurement of bladder wall stretch [62]. Microneedles are a popular areas of research. Their placement onto the skin can allow sampling from interstitial fluid with many glucose and lactate systems proving popular in the literature. Other microneedle type devices include a microneedle patch for the measurement of 'levodopa' which is an important drug used to treat Parkinson's disease [63]. The ability to measure the concentration of the drug in the blood allows consistent dosing to be realized. Wearability also extends to the concept of 'tattoo' biosensors where conductive inks are deployed onto skin to sense biochemical changes [64]. Figure 3 gives an example of tattoo based sensor systems for a range of biochemicals, achieved by placement of colorimetric ink on the skin. The tattoos probe interstitial fluid with pH, glucose and albumin measured at




Figure 3. Overview of a dermal tattoo sensor produced using colorimetric inks for measurement of pH, glucose and albumin in interstitial fluid [64]. (Online version in colour.)

physiologically relevant concentrations and using quantification provided by smart phone imaging. This technique may be useful in wild animals that are either regularly sighted (e.g. on nests, in territories, etc.) or that can be remotely observed e.g. from a bird hide. It may also be a useful technique in managed animals, for example, farmed pigs. For the interested reader, the area of wearables and in particular tattoos and microneedles is well reviewed elsewhere [65]. The concept of wearable extends beyond placement on the skin to areas such as smart clothing and devices woven into fabric. An example, recent study in this area reports near-field-enabled clothing capable of real time networked multi-mode measurement of spinal posture and continuous monitoring of body temperature and gait during exercise [37]. This is achieved through use of woven conductive fibres, rather than silicon components, which can be fragile. Currently, tracking devices are often attached to migrating birds using harnesses that pass between the wings or birds legs [66], and it would be easy to envisage such textile technology integrated to gather physiological measurements that

could be relayed to the tracking device, and onwards remotely to researchers via GSM.

5. Developments in sensor chemistry

In order for a biosensor system to achieve the desired selectivity, it is necessary to develop enhanced chemical/biological receptors, new surface functionalization chemistries (particularly ones which are resistant to bio-fouling) and finally exploit the enhanced sensitivity offered through adoption of nanoscale sensing elements. Again, there have been developments in these fields, specifically directed at solving human medical challenges which may find use in new technologies for wild animal monitoring. The first and most obvious thing to consider is the biorecognition element itself and the advances made to improve performance of biosensing technology through this route. Traditionally biosensor systems have involved the use of enzymes, antibodies, oligonucleotide probe sequences, etc. to achieve the desired specificity for the analyte of interest. While effective, these

379 bio-recognition elements are subject to the disadvantage of
380 relative instability (tendency of antibodies and enzymes to
381 denature over time) which lead to storage problems and
382 lack of long-term functionality. New developments are aug-
383 menting existing approaches and include the maturation of
384 the field of 'molecularly imprinted polymers (MIPs)', giving
385 rise to selective polymer films and nanoparticles with high
386 affinities for their analytes and critically high stability mean-
387 ing long-term storage and use of MIP functionalised sensors
388 is becoming highly feasible. An example of an interesting
389 advance in this field is the use of the nano-MIP, which is a
390 nanoparticle bearing high affinity binding sites for the analyte
391 of interest, to detect epidermal growth factor receptor EGFR
392 using a thermistor [67]. Another promising development in
393 improving the durability and longevity of bioreceptors is the
394 ensilication process. Studies have been published showing
395 the possibility of stabilizing protein structures such as vaccines
396 and antibodies by ensilication a method of silica based cross
397 linking with one study of note using the process to stabilize
398 the tetanus antigen in a vaccine preparation [68] giving the
399 vaccine enhanced thermal storage and reduced tendency to
400 degrade. This type of approach has immense promise to
401 lengthen the active life of biological receptors and improve
402 their usability and shelf life in a biosensor product. It is evi-
403 dent that this will make the monitoring of wild animals
404 much more feasible because sensor units will not have to be
405 changed as often or from one sensor, a much longer measure-
406 ment window will be possible. Although it varies by taxa, in
407 many studies, there is extremely limited opportunity to recap-
408 ture study animals, and sometimes researchers must wait a
409 year to recapture an animal when it returns to breed. Another
410 approach, which is proving increasingly popular in detection
411 science and which is beginning to enable live monitoring is
412 the use of aptamers. Aptamers are DNA sequences which
413 under specific conditions take on three-dimensional structures
414 giving rise to specific binding motifs, not unlike antibodies
415 and with similar K_D values. It is possible through a directed
416 evolution process known as SELEX to generate aptamers
417 with high specificity for individual analytes. The advantages
418 of these agents as the binding element in a sensor is the ability
419 to tailor binding kinetics, the ability to produce sequences
420 quickly with a range of standard and non-standard chemical
421 modifications (surface attachment groups, florescent labels,
422 redox labels, etc.) and the increase in longevity which is
423 gained when aptamers replace antibodies as the bio-recog-
424 nition element. A relatively recent and elegant study shows
425 the use of an implanted electrochemical aptamer based
426 sensor to measure drug concentrations in the blood of ambu-
427 latory rats with high sensitivity and good temporal resolution
428 (3 s) [69]. Another impressive study shows the use of an apta-
429 mer functionalised array in combination with a robotically
430 controlled sample handler to measure luteinizing hormone
431 and therefore hormone 'pulsatility' in patients with reproduc-
432 tive conditions [70]. These are interesting studies because they
433 highlight routes, either through direct sampling of animal
434 populations or through use of wearable devices to the possi-
435 bility of sampling physiological pulsing, hormones,
436 antimicrobials or pollutants in the circulatory systems of
437 wild animals. Indeed, the measurement of adrenocorticotrophic
438 hormones, glucocorticoid stress hormones (e.g. cortisol), thy-
439 roid hormones (such as leptin, insulin and glucagon),
440 melatonin (regulating the 'biological clock') over long periods
441 (months) would shed light on some of the most dramatic

periods in wild animals lives, such as breeding, moulting
and migration [58].

Following on from developments which prolong the life-
time of the bio-recognition element through synthetic
alternatives or stabilization chemistry, attempts are being
made to replace the biological element of a biosensor
altogether. One very pertinent example is the 'enzyme free'
glucose biosensor. In these systems, nanomaterials are
employed because of their high catalytic activity and ability
to selectively oxidise glucose at moderate voltages (meaning
there are low background interference currents from other
common analytes). The benefit of enzyme free glucose bio-
sensors again relates to the gains offered in the final sensor
system's working life. Enzymes lose activity over time and
this is a key limitation on wearable glucose monitors (to cir-
cumvent this issue, replacement sensors are used every few
months). Recent examples of non-enzymatic glucose biosen-
sors include: a system on a glass substrate composed of
hydrothermally grown CuO nanorods decorated with Au
nanoparticles and used to detect glucose levels in saliva
[71], the development of a metal oxide sensor induced by
an electrical potential to non-enzymatically detect glucose
in artificial tears via wireless connection [72] and use of a
Ni₆₀Nb₄₀ amorphous nanoglass composite to non-enzymati-
cally detect glucose with 100 nM sensitivities opening up
the potential of using nickel based nanoglasses in wearable
sensors [73]. All of these systems are offering the sensitivity
and selectivity required to measure glucose in blood, sweat
and interstitial fluid and so it seems inevitable that products
based on this approach will reach the blood glucose monitor-
ing market.

A crucial issue in implantable sensing is the tendency of
proteins and cells from biofluids to adhere to the transducer
element of a sensor and complicate the measurement by
affecting the analytical response of the device. This phenom-
enon is often referred to as 'biofouling', is different from the
biofouling which affects marine sensors and is a key reason
why implanted detection of blood based biomarkers in
human subjects has not yet reached maturity. Such biofouling
has been a persistent issue in the physiological telemetry of
wild animals, particularly in extreme habitats such as the
frozen Antarctic seas. The issue of biofouling is key area of
biosensor research with many groups working on improved
surface chemistries or gel based systems which reduce bio-
fouling and improve the reporting of a device's true
analytical response. The ability to precisely control the for-
mation of hydrogels was shown in a study which used
nanoelectrode structures to monitor the formation of gels in
real time and then used the underlying electrode as a sensor
for specific drug resistance DNA gene sequences with the
formed hydrogel behaving as a filter, effectively screening
out background interferents to improve the analytical response
of the device [74].

6. Synthetic biology approaches to biomedical sensing

Synthetic biology as referred to in this article means the use of
cells and biochemical machinery to engineer novel biosen-
sors. This technique has many advantages and these
include: the use of already existing enzymes, proteins and
nucleic acid sequences, the molecular biology field has

442 matured allowing easy modification and characterization of
443 synthetic systems, high biocompatibility and the existence
444 of manufacturing techniques and production processes for
445 high volumes of sensor reagents. A recent and popular devel-
446 opment has been to engineer biosensors which employ the
447 CRISPR-Cas gene systems for the purposes of detection of
448 specific nucleic acid sequences. For example, the CRISPR-
449 Cas9 system has been recently used to develop biosensors
450 for tumour microRNAs (miR-19b and miR-20a) with times
451 to result of less than 4 h and sensitivities as low as 10 pM
452 [75]. In addition to this, the CRISPR-Cas12a system was
453 developed for detection of the Epstein-Bar virus in a lateral
454 flow/point of care format [76]. Other approaches involve
455 genetic engineering and the use of genetic circuits in combi-
456 nation with microelectronics to detect analytes of interest,
457 for example, the detection of heavy metals present in bacteria
458 through use of engineered genetic circuits [77].

460 7. Future perspectives (antimicrobial resistance 461 and zoonotic infections)

462 Antimicrobial resistance (AMR) is typically seen as a problem
463 affecting only humans with its emergence and spread having
464 potentially dire consequences for the global population. To
465 provide further context, if left unaddressed, by 2050 AMR
466 is expected to account for more deaths per year than cancer
467 and diabetes combined. The phenomenon of AMR is driven
468 by many factors which include: inappropriate prescriptions,
469 the fact that a proportion of countries allow over the counter
470 purchasing in pharmacies, shortages of new antimicrobials,
471 the overuse of antibiotics in agriculture and ineffective
472 environmental controls (particularly in manufacture and dis-
473 posal) which facilitate accumulation in the environment. To
474 try and alleviate some of the present and predicted problems,
475 governments are trying to stimulate innovation through
476 encouraging the development of new antimicrobial com-
477 pounds, encouraging good antibiotic stewardship and
478 stimulating the development of new diagnostic tests in the
479 hope that the technology will reach a performance level
480 where antibiotic prescriptions can be made contingent on a
481 confirmatory test. Technological advances in the area of
482 AMR diagnostics have the general aim of producing low
483 cost, sub half hour testing technologies. Since AMR is in fact
484 not just a human problem (due to the widespread prevalence
485 of residual antibiotics in the environment) drug resistant infec-
486 tions will become an increasing problem for free living and
487 farm animals and the new diagnostic tests which are designed
488 to be low cost and simple to use will enhance the study of
489 AMR in populations of wild animals and improve antibiotic
490 stewardship in the veterinary sector. Biosensor technology
491 could also be used in the future in managed (agriculture and
492 aquaculture) systems as a surveillance technology to proac-
493 tively detect infections before antibiotic treatment is given,
494 which may help to reduce the total use of antibiotics.

495 Recent developments in the field of diagnostic tests for
496 AMR can be divided into two major groups; phenotypic
497 and genotypic tests. In a broad sense, phenotypic tests gener-
498 ally attempt to recreate classical microbiological strategies of
499 growing bacteria and assessing their antibiotic susceptibility
500 profiles. A number of innovative platforms have been devel-
501 oped which include gel modified electrode sensors capable of
502 discriminating between *S. Aureus* and MRSA in under 1 h

[78], the use of the redox agent potassium ferricyanide to
report bacterial respiration in antibiotic infused cultures
[79], a capillary based optical platform capable of AST results
with 4–8 h [80], and the use of microfluidic platforms in
combination with the commonly employed respiration rate
sensitive compound resazurin to quickly determine antibiotic
susceptibility from a sample [81,82]. Genotypic sensors have
been developed for detection of AMR which directly probe
for the presence of specific gene sequences indicative of bac-
terial species and any resistance genes [29,83]. These tests
give more information because they probe the genetic basis
of the resistance but still require careful interpretation
because the presence of a particular drug resistance gene
does not always confer resistance upon a pathogen, some-
times additional transcription factors and other genes are
necessary to produce a drug resistant phenotype.

Given the situation the world currently finds itself in, i.e.
in the midst of a pandemic caused by the SARS-CoV-2 virus
which is thought to have originated in bats, potentially cross-
ing to humans via an intermediary mammalian species, it is
important to raise the use of biosensor technologies for moni-
toring virus transfer and mutation between wild animals.
Monitoring will be particularly important in animals which
are responsible for a large number of zoonotic infections
(e.g. birds and bats) with technologies which can fill this
space offering the ability to quickly pinpoint and hopefully
suppress the development of viral strains with pandemic caus-
ing potential. Indeed, the power and scale of existing
structured sampling of zoonoses in wild animals (e.g. from
faeces from bat roosts) would benefit enormously, and
rapidly, from such technology [84].

Work dedicated to the detection of viral infections of the
human population includes detection of Ebola virus [85]
using an array of nano-antennae. Ebola is a serious and
recurring threat to human health with regular outbreaks
necessitating the development of low cost, simple to use
and innovative diagnostic technologies. Another viral infec-
tion which gained large amounts of attention in recent
years is Zika, the enzoonotic virus with a life cycle involving
monkeys and mosquitoes. Here, sensor technologies have
been developed to detect live virus using an imprinted
sensor surface [86] but also crucially to profile blood for the
presence of Zika antibodies [87] in order to map spread
within communities and regions. The prospect of pandemics,
particularly those of an avian origin and especially respira-
tory pathogens has long concerned biosensor scientists [88]
and the response to the need for diagnostic devices for
COVID-19 has seen alongside widespread adoption and
upscaling of traditional methods, the emergence of novel
approaches such as field-effect-transistor based system
[89] for COVID detection in nasopharyngeal swabs. As
the COVID-19 pandemic continues, innovative biosensor
solutions are emerging, for example application of the
synthetic biology CRISPR-Cas system to SARS-CoV-2
detection [90] and single tube reverse transcription loop
mediated isothermal amplification (RT-LAMP) techniques
[91]. The emergence of new diagnostic solutions which
the COVID-19 outbreak is accelerating means that identify-
ing and tracking animal populations harbouring pathogenic
strains will become easier and hopefully in more wide-
spread use, perhaps increasing the opportunity to track
and eliminate potential outbreaks of viruses with pandemic
causing potential.

8. Potential for cutting edge technology to cross over into animal monitoring

The review has highlighted a number of papers which showcase state of the art advances in micro systems engineering and chemical science which have given rise to new approaches to monitoring human health. These advances all have the potential to contribute to monitoring of physiological status in wild animals. Implantable and wearable devices show the most promise for long-term monitoring of animals and developments which prolong the lifetime of the biosensing element are crucial because at present, denaturation of antibodies or enzymes over time and the need to either swap or recalibrate the sensor are a major limitation on prolonged and unsupervised use. Advances in human monitoring which sample less invasively by taking measurements from interstitial fluid, sweat or tears are of interest to animal monitoring because they negate the requirement for an invasive test. Patch-type wearable physiological devices [92] would also provide data in a less invasive manner than used at present (physiological devices are often surgically implanted in wild animal research). As has been discussed in the review, sampling of analytes such as glucose and lactate from biofluids is now being achieved using a whole range of innovative technologies intended for human use. Adapting these devices for animal use will involve making sure the instrumentation can access the correct fluid sample and this will involve giving consideration to the differences in the animal of interest's own physiology and the accessibility and availability of the biofluids needing to be sampled. A theme which will emerge in human medical technologies in the near future will be routine monitoring of more complex biomarkers (e.g. other than glucose, lactate and pH) and

this includes biomarkers diagnostic of inflammatory changes (sepsis, bacterial versus non bacterial infection), neurological status (e.g. blood-based biomarkers for dementia) and cancer (circulating tumour DNA and circulating tumour cells). Following maturation of these technologies in humans, it will be possible to deploy them in animals in order to track the effects of pollution (e.g. antimicrobials, micro-plastics) and the effects of climate change (through e.g. spread of parasitic diseases). In addition, the increasing simplicity of these technologies, the potential to interface with smart phones and the lack of requirements for sample handling will hopefully assist with design and realization of less invasive and more easily deployed devices (still with potential to cause distress during application to animals) which give genuine insight into the physiological status of wild animals. Such insights would not only revolutionize the study of wild animal physiology, but would also reveal the mechanisms with which wild animals have mastered many of the future challenges to human society (obesity, diabetes, zoonoses and AMR).

Data accessibility. This article has no additional data.

Authors' contributions. The authors conceived, wrote and edited the manuscript together. A.M. and D.C. focused on engineering/chemistry developments and LH on major issues in animal monitoring.

Competing interests. We declare we have no competing interests.

Funding. We received no funding for this study.

Acknowledgements. A.M.'s EngD studentship is funded by the EPSRC CDT in Biomedical Devices and Health Technologies (EP/L015595/1).

Endnote

¹<https://www.who.int/csr/don/06-november-2020-mink>.

References

- Wang J. 2008 Electrochemical glucose biosensors. *Chem. Rev.* **108**, 814–825. (doi:10.1021/cr068123a)
- Sosna M, Denuault G, Pascal RW, Prien RD, Mowlem M. 2007 Development of a reliable microelectrode dissolved oxygen sensor. *Sensors Actuators, B Chem.* **123**, 344–351. (doi:10.1016/j.snb.2006.08.033)
- Corrigan DK, Elliott JP, Blair EO, Reeves S, Schmäser I, Walton AJ, Mount AR. 2016 Advances in electroanalysis, sensing and monitoring in molten salts. *Faraday Discuss.* **190**, 351–366. (doi:10.7488/ds/1338)
- Corrigan DK, Whitcombe MJ, McCrossen S, Piletsky S. 2009 Reichardt's dye and its reactions with the alkylating agents 4-chloro-1-butanol, ethyl methanesulfonate, 1-bromobutane and Fast Red B - a potentially useful reagent for the detection of genotoxic impurities in pharmaceuticals. *J. Pharm. Pharmacol.* **61**, 533–537. (doi:10.1211/jpp.61.04.0017)
- Corrigan DK, Salton NA, Preston C, Piletsky S. 2010 Towards the development of a rapid, portable, surface enhanced Raman spectroscopy based cleaning verification system for the drug nelarabine. *J. Pharm. Pharmacol.* **62**, 1195–1200. (doi:10.1111/j.2042-7158.2010.01152.x)
- Scognamiglio V, Arduini F. 2019 The technology tree in the design of glucose biosensors. *TrAC - Trends Anal. Chem.* **120**, 115642. (doi:10.1016/j.trac.2019.115642)
- Kucherenko IS, Topolnikova YV, Soldatkin OO. 2019 Advances in the biosensors for lactate and pyruvate detection for medical applications: a review. *TrAC - Trends Anal. Chem.* **110**, 160–172.
- Aria MM, Erten A, Yalcin O. 2019 Technology advancements in blood coagulation measurements for point-of-care diagnostic testing. *Front. Biotechnol. Bioeng.* **7**, 1–18. (doi:10.3389/fbioe.2019.00395)
- Stockard TK, Heil J, Meir JU, Sato K, Ponganis KV, Ponganis PJ. 2005 Air sac P_O₂ and oxygen depletion during dives of emperor penguins. *J. Exp. Biol.* **208**, 2973–2980. (doi:10.1242/jeb.01687)
- Kim J, Campbell AS, Wang J. 2018 Wearable non-invasive epidermal glucose sensors: a review. *Talanta* **177**, 163–170. (doi:10.1016/j.talanta.2017.08.077)
- Homayounfar SZ, Andrew TL. 2020 Wearable sensors for monitoring human motion: a review on mechanisms, materials, and challenges. *SLAS Technol.* **25**, 9–24. (doi:10.1177/2472630319891128)
- Currano LJ, Sage FC, Hagedon M, Hamilton L, Patrone J. 2018 Wearable sensor system for detection of lactate in sweat. *Sci. Rep.* **8**, 1–11. (doi:10.1038/s41598-018-33565-x)
- Guglielmo CG. 2018 Obese super athletes: fat-fueled migration in birds and bats. *J. Exp. Biol.* **221**, jeb165753. (doi:10.1242/jeb.165753)
- Braun EJ, Sweazea KL. 2008 Glucose regulation in birds. *Comp. Biochem. Physiol. B Biochem. Mol. Biol.* **151**, 1–9. (doi:10.1016/j.cbpb.2008.05.007)
- Fago A, Jensen FB. 2015 Hypoxia tolerance, nitric oxide, and nitrite: lessons from extreme animals. *Physiology* **30**, 116–126. (doi:10.1152/physiol.00051.2014)
- Ponganis PJ. 2019 State of the art review: from the seaside to the bedside: insights from comparative diving physiology into respiratory, sleep and critical care. *Thorax* **74**, 512 LP–512518. (doi:10.1136/thoraxjnl-2018-212136)
- Nabi G, Wang Y, Lü L, Jiang C, Ahmad S, Wu Y, Li D. 2021 Bats and birds as viral reservoirs: a physiological and ecological perspective. *Sci. Total Environ.* **754**, 142372. (doi:10.1016/j.scitotenv.2020.142372)
- Whitford M, Klimley AP. 2019 An overview of behavioral, physiological and environmental sensors

- used in animal biotelemetry and biologging studies. *Anim. Biotelem.* **7**, 1–24. (doi:10.1186/s40317-019-0189-z)
19. Kelly JT, Klimley AP. 2012 Relating the swimming movements of green sturgeon to the movement of water currents. *Environ. Biol. Fishes* **93**, 151–167. (doi:10.1007/s10641-011-9898-8)
20. Brown DD, Kays R, Wikelski M, Wilson R, Klimley AP. 2013 Observing the unwatchable through acceleration logging of animal behavior. *Anim. Biotelem.* **1**, 1–16.
21. Tift MS, Hu LA, McDonald BI, Thorson PH, Ponganis PJ. 2017 Flipper stroke rate and venous oxygen levels in free-ranging California sea lions. *J. Exp. Biol.* **220**, 1533–1540. (doi:10.1242/jeb.152314)
22. Murgatroyd M, Amar A, Africa S. 2018 Where eagles soar: fine-resolution tracking reveals the spatiotemporal use of differential soaring modes in a large raptor. *Ecol. Evol.* **8**, 6788–6799. (doi:10.1002/ece3.4189)
23. Coffey DM, Holland KN. 2015 First autonomous recording of in situ dissolved oxygen from free-ranging fish. *Anim. Biotelem.* **3**, 1–9. (doi:10.1186/s40317-015-0088-x)
24. McDonald BI, Tift MS, Hu LA, Jeffko M, Ponganis PJ. 2020 Stroke effort and relative lung volume influence heart rate in diving sea lions. *J. Exp. Biol.* **223**. (doi:10.1242/jeb.214163)
25. Scriba MF, Harmening WM, Vyssotski AL, Roulin A, Wagner H, Rattenborg NC. 2013 Evaluation of two minimally invasive techniques for electroencephalogram recording in wild or freely behaving animals. *J. Comp. Physiol. A Neuroethol. Sens. Neural Behav. Physiol.* **3**, 183–189. (doi:10.1007/s00359-012-0779-1)
26. Thouzeau C, Peters G, Le Bohec C, Le Maho Y, Cedex F-S, Technologies O, Strasse H. 2004 Adjustments of gastric pH, motility and temperature during long-term preservation of stomach contents in free-ranging incubating king penguins. *J. Exp. Biol.* **207**, 2715–2724. (doi:10.1242/jeb.010704)
27. Bennett KA, Turner LM, Millward S, Moss SEW, Hall AJ. 2017 Obtaining accurate glucose measurements from wild animals under field conditions: comparing a hand held glucometer with a standard laboratory technique in grey seals. *Conserv. Physiol.* **5**, 1–10. (doi:10.1093/conphys/cox013)
28. Pei J, Neo S, Tan BH. 2017 The use of animals as a surveillance tool for monitoring environmental health hazards, human health hazards and bioterrorism. *Vet. Microbiol.* **203**, 40–48. (doi:10.1016/j.vetmic.2017.02.007)
29. Blair EO, Hannah S, Vezza V, Avci H, Kocagöz T, Hoskisson PA, Güzel FD, Corrigan DK. 2020 Biologically modified microelectrode sensors provide enhanced sensitivity for detection of nucleic acid sequences from *Mycobacterium tuberculosis*. *Sensors Actuators Rep.* **2**, 100008. (doi:10.1016/j.snr.2020.100008)
30. Terry JG, Schmüser I, Underwood I, Corrigan DK, Freeman NJ, Bunting AS, Mount AR, Walton AJ. 2013 Nanoscale electrode arrays produced with microscale lithographic techniques for use in biomedical sensing applications. *IET Nanobiotechnol.* **7**, 125–134. (doi:10.1049/iet-nbt.2013.0049)
31. Patil AC, Thakor NV. 2016 Implantable neurotechnologies: a review of micro-and nanoelectrodes for neural recording. *Med. Biol. Eng. Comput.* **54**, 23–44. (doi:10.1007/s11517-015-1430-4)
32. Aulsebrook AE, Connelly F, Johnsson RD, Jones TM, Mulder RA, Hall ML, Vyssotski AL, Lesku JA. 2020 White and amber light at night disrupt sleep physiology in birds. *Curr. Biol.* **30**, 3657–3663.e5. (doi:10.1016/j.cub.2020.06.085)
33. Vyssotski AL, Dell’Omo G, Dell’Ariccia G, Abramchuk AN, Serkov AN, Latanov AV, Loizzo A, Wolfer DP, Lipp H-P. 2009 EEG responses to visual landmarks in flying Pigeons. *Curr. Biol.* **19**, 1159–1166. (doi:10.1016/j.cub.2009.05.070)
34. van Hasselt SJ, Rusche M, Vyssotski AL, Verhulst S, Rattenborg NC, Meerlo P. 2020 Sleep time in the European starling is strongly affected by night length and moon phase. *Curr. Biol.* **30**, 1664–1671.e2. (doi:10.1016/j.cub.2020.02.052)
35. Scharf R, Tsunematsu T, Mcalinden N, Dawson MD, Sakata S, Mathieson K. 2016 Depth-specific optogenetic control in vivo with a scalable, high-density μ LED neural probe. *Nat. Publ. Gr.* 1–10. (doi:10.1038/srep28381)
36. Liu C, Zhao Y, Cai X, Xie Y, Wang T, Cheng D, Li L, Li R, Deng Y. 2020 A wireless, implantable optoelectrochemical probe for optogenetic stimulation and dopamine detection. *Microsystems Nanoeng.* **6**, 1–2. (doi:10.1038/s41378-020-0176-9)
37. Zhang Y *et al.* 2019 Battery-free, lightweight, injectable microsystem for in vivo wireless pharmacology and optogenetics. *Proc. Natl Acad. Sci. USA* **116**, 21 427–21 437. (doi:10.1073/pnas.1909850116)
38. Angotzi GN, Boi F, Lecomte A, Miele E, Malerba M, Zucca S, Casile A, Berdondini L. 2019 SiNAPS: an implantable active pixel sensor CMOS-probe for simultaneous large-scale neural recordings. *Biosens. Bioelectron.* **126**, 355–364. (doi:10.1016/j.bios.2018.10.032)
39. Rattenborg NC, Voirin B, Cruz SM, Tisdale R, Dell’Omo G, Lipp H-P, Wikelski M, Vyssotski AL. 2016 Evidence that birds sleep in mid-flight. *Nat. Commun.* **7**, 12468. (doi:10.1038/ncomms12468)
40. Kendall-Bar JM, Vyssotski AL, Mukhametov LM, Siegel JM, Lyamin OI. 2019 Eye state asymmetry during aquatic unihemispheric slow wave sleep in northern fur seals (*Callorhinus ursinus*). *PLoS ONE* **14**, e0217025. (doi:10.1371/journal.pone.0217025)
41. Dryden MDM, Wheeler AR. 2015 DStat: a versatile, open-source potentiostat for electroanalysis and integration. *PLoS ONE* **10**, e0140349. (doi:10.1371/journal.pone.0140349)
42. Lopin P, Lopin KV. 2018 PSoC-Stat: a single chip open source potentiostat based on a programmable system on a chip. *PLoS ONE* **13**, e0201353. (doi:10.1371/journal.pone.0201353)
43. Butterworth A, Corrigan DK, Ward AC. 2019 Electrochemical detection of oxacillin resistance with SimpleStat: a low cost integrated potentiostat and sensor platform. *Anal. Methods* **11**, 1958–1965. (doi:10.1039/c9ay00383e)
44. Sánchez C, Dessì P, Duffy M, Lens PNL. 2020 Microbial electrochemical technologies: electronic circuitry and characterization tools. *Biosens. Bioelectron.* **150**, 111884. (doi:10.1016/j.bios.2019.111884)
45. Mercer C, Bennett R, Conghaile PÓ, Rusling JF, Leech D. 2019 Glucose biosensor based on open-source wireless microfluidic potentiostat. *Sensors Actuators B: Chem* **290**, 616–624. (doi:10.1016/j.snb.2019.02.031)
46. Roknsharif M, Kamrul S, Kai I, Ifana Z. 2015 A low power, highly stabilized three electrode potentiostat for biomedical implantable systems. *Analog Integr. Circuits Signal Process.* **83**, 217–229. (doi:10.1007/s10470-015-0524-0)
47. Rabby MK, Alam MS, Shawkat MS. 2019 A priority based energy harvesting scheme for charging embedded sensor nodes in wireless body area networks. *PLoS ONE* **14**, 1–22. (doi:10.1371/journal.pone.0214716)
48. Yi Z *et al.* 2020 A battery- and leadless heart-worn pacemaker strategy. *Adv. Funct. Mater.* **30**, 2000477. (doi:10.1002/adfm.202000477)
49. Bodey TW, Cleasby IR, Bell F, Parr N, Schultz A, Votier SC, Bearhop S. 2018 A phylogenetically controlled meta-analysis of biologging device effects on birds: deleterious effects and a call for more standardized reporting of study data. *Methods Ecol. Evol.* **9**, 946–955. (doi:10.1111/2041-210X.12934)
50. Authier M, Péron C, Mante A, Vidal P, Grémillet D. 2013 Designing observational biologging studies to assess the causal effect of instrumentation. *Methods Ecol. Evol.* **4**, 802–810. (doi:10.1111/2041-210X.12075)
51. Gray ME *et al.* 2019 *In vivo* validation of a miniaturized electrochemical oxygen sensor for measuring intestinal oxygen tension. *Am. J. Physiol. - Gastrointest. Liver Physiol.* **317**, 242–252. (doi:10.1152/ajpgi.00050.2019)
52. Marland JRK *et al.* 2020 Real-time measurement of tumour hypoxia using an implantable microfabricated oxygen sensor. *Sens. Bio-Sensing Res.* **30**, 100375. (doi:10.1016/j.sbsr.2020.100375)
53. Christiansen MP, Klaff LJ, Bailey TS, Brazg R, Carlson G, Tweden KS. 2019 A prospective multicenter evaluation of the accuracy and safety of an implanted continuous glucose sensor: the precision study. *Diabetes Technol. Ther.* **21**, 231–237. (doi:10.1089/dia.2019.0020)
54. Torres-Martinez N, Ratel D, Crétallaz C, Gaude C, Maubert S, Divoux JL, Henry C, Guiraud D, Sauter-Starace F. 2019 Reliability of parylene-based multi-electrode arrays chronically implanted in adult rat brains, and evidence of electrical stimulation on contact impedance. *J. Neural Eng.* **16**, 066047. (doi:10.1088/1741-2552/ab3836)
55. Nightingale AM, Leong CL, Burnish RA, Hassan S, Zhang Y, Clough GF, Boutelle MG, Voegeli D, Niu X. 2019 Monitoring biomolecule concentrations in tissue using a wearable droplet microfluidic-based

- 631 sensor. *Nat. Commun.* **10**, 1–12. (doi:10.1038/
- 632 s41467-019-10401-y)
- 633 56. Zhao Y, Zhai Q, Dong D, An T, Gong S, Shi Q, Cheng
- 634 W. 2019 Highly stretchable and strain-insensitive
- 635 fiber-based wearable electrochemical biosensor to
- 636 monitor glucose in the sweat. *Anal. Chem.* **91**,
- 637 6569–6576. (doi:10.1021/acs.analchem.9b00152)
- 638 57. Bae CW, Toi PT, Kim BY, Lee II WI, Lee HB, Hanif A,
- 639 Lee EH, Lee NE. 2019 Fully stretchable capillary
- 640 micro fluidics-integrated nanoporous gold
- 641 electrochemical sensor for wearable continuous
- 642 glucose monitoring. *ACS Appl. Mater. Interfaces* **11**,
- 643 14 567–14 575. (doi:10.1021/acsmi.9b00848)
- 644 58. Jachowski DS, Singh NJ. 2015 Toward a mechanistic
- 645 understanding of animal migration: incorporating
- 646 physiological measurements in the study of animal
- 647 movement. *Conserv. Physiol.* **3**, cov035. (doi:10.
- 648 1093/conphys/cov035)
- 649 59. Shepard ELC, Wilson RP, Rees WG, Grundy E,
- 650 Lambertucci SA, Vosper SB. 2013 Energy landscapes
- 651 shape animal movement ecology. *Am. Nat.* **182**,
- 652 298–312. (doi:10.1086/671257)
- 653 60. Biron BM, Ayala A, Lomas-Neira JL. 2015 Biomarkers
- 654 for sepsis: what is and what might be? *Biomark.*
- 655 *Insights* **10**, 7–17. (doi:10.4137/BMI.S29519)
- 656 61. Kooyman GL, McDonald BI, Williams CL, Meir JU,
- 657 Ponganis PJ. 2021 The aerobic dive limit: after 40
- 658 years, still rarely measured but commonly used.
- 659 *Comp. Biochem. Physiol. Part A Mol. Integr. Physiol.*
- 660 **252**, 110841. (doi:10.1016/j.cbpa.2020.110841)
- 661 62. Hannah S, Brige P, Ravichandran A, Ramuz M. 2019
- 662 Conformable, stretchable sensor to record bladder
- 663 wall stretch. *ACS Omega* **4**, 4–12. (doi:10.1021/
- 664 acsomega.8b02609)
- 665 63. Goud KY, Moonla C, Mishra RK, Yu C, Narayan R,
- 666 Litvan I, Wang J. 2019 Wearable electrochemical
- 667 microneedle sensor for continuous monitoring of
- 668 levodopa: toward Parkinson management. *ACS Sens.*
- 669 **4**, 2196–2204. (doi:10.1021/acssensors.9b01127)
- 670 64. Yetisen AK *et al.* 2019 Dermal tattoo biosensors for
- 671 colorimetric metabolite detection. *Angew. Chemie*
- 672 **131**, 10 616–10 623. (doi:10.1002/ange.201904416)
- 673 65. Hosu O, Mirel S, Săndulescu R, Cristea C. 2019
- 674 Minireview: smart tattoo, microneedle, point-of-
- 675 care, and phone-based biosensors for medical
- 676 screening, diagnosis, and monitoring. *Anal. Lett.* **52**,
- 677 78–92. (doi:10.1080/00032719.2017.1391826)
- 678 Q3 66. Geen GR, Robinson RA, Baillie SR. 2019 Effects of
- 679 tracking devices on individual birds – a review of the
- 680 evidence. *J. Avian Biol.* **50**. (doi:10.1111/jav.01823)
- 681 67. Betlem K *et al.* 2020 Thermistors coated with
- 682 molecularly imprinted nanoparticles for the
- 683 electrical detection of peptides and proteins. *Analyst*
- 684 **145**, 5419–5424. (doi:10.1039/d0an01046d)
- 685 68. Doekhie A *et al.* 2020 Ensilicated tetanus antigen
- 686 retains immunogenicity: in vivo study and time-
- 687 resolved SAXS characterization. *Sci. Rep.* **10**, 1–9.
- 688 (doi:10.1038/s41598-020-65876-3)
- 689 69. Arroyo-Currás N, Somerson J, Vieira PA, Ploense KL,
- 690 Kippin TE, Plaxco KW. 2017 Real-time measurement
- 691 of small molecules directly in awake, ambulatory
- 692 animals. *Proc. Natl Acad. Sci. USA* **114**, 645–650.
- 693 (doi:10.1073/pnas.1613458114)
- 694 70. Liang S *et al.* 2019 Measuring luteinising hormone
- 695 pulsatility with a robotic aptamer-enabled
- 696 electrochemical reader. *Nat. Commun.* **10**, 1–10.
- 697 (doi:10.1038/s41467-019-08799-6)
- 698 71. Chakraborty P, Dhar S, Debnath K, Majumder T,
- 699 Mondal SP. 2019 Non-enzymatic and non-invasive
- 700 glucose detection using Au nanoparticle decorated
- 701 CuO nanorods. *Sensors Actuators. B Chem.* **283**,
- 702 776–785. (doi:10.1016/j.snb.2018.12.086)
- 703 72. Strakosas X, Selberg J, Pansodtee P, Yonas N,
- 704 Manapongpun P, Teodorescu M, Rolandi M. 2019 A
- 705 non-enzymatic glucose sensor enabled by
- 706 bioelectronic pH control. *Sci. Rep.* **9**, 1–7. (doi:10.
- 707 1038/s41598-019-46302-9)
- 708 73. Bag S, Baksi A, Nandam SH, Wang D, Ye X, Ghosh J,
- 709 Pradeep T, Hahn H. 2020 Nonenzymatic glucose
- 710 sensing using Ni60Nb40 nanoglass. *ACS Nano* **14**,
- 711 5543–5552. (doi:10.1021/acsnano.9b09778)
- 712 74. Piper A, Alston BM, Adams DJ, Mount AR. 2018
- 713 Functionalised microscale nanoband edge electrode
- 714 (MNEE) arrays: the systematic quantitative study of
- 715 hydrogels grown on nanoelectrode biosensor arrays
- 716 for enhanced sensing in biological media. *Faraday*
- 717 *Discuss.* **210**, 201–217. (doi:10.1039/C8FD00063H)
- 718 75. Bruch R, Baaske J, Chatelle C, Meirich M, Madlener
- 719 S, Weber W, Dincer C, Urban GA. 2019 CRISPR/
- 720 Cas13a-powered electrochemical microfluidic
- 721 biosensor for nucleic acid amplification-free miRNA
- 722 diagnostics. *Adv. Mat.* **31**, 1905311. (doi:10.1002/
- 723 adma.201905311)
- 724 76. Yuan T *et al.* 2020 A rapid and sensitive CRISPR/
- 725 Cas12a based lateral flow biosensor for the
- 726 detection of Epstein–Barr virus. *Analyst* **145**,
- 727 6388–6394. (doi:10.1039/d0an00663g)
- 728 77. Din MO, Martin A, Razinkov I, Csicsery N, Hasty J.
- 729 2020 Interfacing gene circuits with microelectronics
- 730 through engineered population dynamics. *Sci. Adv.*
- 731 **6**, eaaz8344.
- 732 78. Hannah S, Addington E, Alcorn D, Shu W, Hoskisson
- 733 PA, Corrigan DK. 2019 Rapid antibiotic susceptibility
- 734 testing using low-cost, commercially available
- 735 screen-printed electrodes. *Biosens. Bioelectron.* **145**,
- 736 111696. (doi:10.1016/j.bios.2019.111696)
- 737 79. Chotinantakul K, Suginta W, Schulte A. 2014
- 738 Advanced amperometric respiration assay for
- 739 antimicrobial susceptibility testing. *Anal. Chem.* **86**,
- 740 10 315–10 322. (doi:10.1021/ac502554s)
- 741 80. Wang R, Vemulapati S, Westblade LF, Glesby MJ,
- 742 Mehta S, Erickson D. 2020 cAST: capillary-based
- 743 platform for real-time phenotypic antimicrobial
- 744 susceptibility testing. *Anal. Chem.* **92**, 2731–2738.
- 745 (doi:10.1021/acs.analchem.9b04991)
- 746 81. Besant JD, Sargent EH, Kelley SO. 2015 Rapid
- 747 electrochemical phenotypic profiling of antibiotic-
- 748 resistant bacteria. *Lab. Chip* **15**, 2799–2807. (doi:10.
- 749 1039/c5lc00375j)
- 750 82. Yang Y, Gupta K, Ekinici KL. 2020 All-electrical
- 751 monitoring of bacterial antibiotic susceptibility in a
- 752 microfluidic device. *Proc. Natl Acad. Sci. USA* **117**,
- 753 10 639–10 644. (doi:10.1073/pnas.1922172117)
- 754 83. Quan Li P, Piper A, Schmuesser I, Mount AR, Corrigan
- 755 DK. 2017 Impedimetric measurement of DNA-DNA
- 756 hybridisation using microelectrodes with different
- 757 radii for detection of methicillin resistant:
- 758 *Staphylococcus aureus* (MRSA). *Analyst* **142**,
- 759 1946–1952. (doi:10.1039/c7an00436b)
- 760 84. Watsa M. 2020 Rigorous wildlife disease
- 761 surveillance. *Science* **369**, 145–147. (doi:10.1126/
- 762 science.abc0017)
- 763 85. Zang F, Su Z, Zhou L, Konduru K, Kaplan G, Chou
- 764 SY. 2019 Ultrasensitive Ebola virus antigen sensing
- 765 via 3D nanoantenna arrays. *Adv. Mat.* **30**, 1902331.
- 766 (doi:10.1002/adma.201902331)
- 767 86. Ricotta V, Yu Y, Clayton N, Chuang YC, Wang Y,
- 768 Mueller S, Levon K, Simon M, Rafailovich M. 2019
- 769 A chip-based potentiometric sensor for a Zika virus
- 770 diagnostic using 3D surface molecular imprinting.
- 771 *Analyst* **144**, 4266–4280. (doi:10.1039/c9an00580c)
- 772 87. Cabral-Miranda G, Cardoso AR, Ferreira LCS, Sales
- 773 MGF, Bachmann MF. 2018 Biosensor-based selective
- 774 detection of Zika virus specific antibodies in infected
- 775 individuals. *Biosens. Bioelectron.* **113**, 101–107.
- 776 (doi:10.1016/j.bios.2018.04.058)
- 777 88. Astill J, Dara RA, Fraser EDG, Sharif S 2018 Detecting
- 778 and predicting emerging disease in poultry with the
- 779 implementation of new technologies and big data:
- 780 a focus on avian influenza virus. *Front. Vet. Sci.* **5**,
- 781 1–12. (doi:10.3389/fvets.2018.00263)
- 782 89. Seo G *et al.* 2020 Rapid detection of COVID-19
- 783 Causative virus (SARS-CoV-2) in human
- 784 nasopharyngeal swab specimens using field-effect
- 785 transistor-based biosensor. *ACS Nano* **14**,
- 786 5135–5142. (doi:10.1021/acsnano.0c02823)
- 787 90. Huang Z *et al.* 2020 Ultra-sensitive and high-
- 788 throughput CRISPR-powered COVID-19 diagnosis.
- 789 *Biosens. Bioelectron.* **164**, 112316. (doi:10.1016/j.
- 790 bios.2020.112316)
- 791 91. Huang WE *et al.* 2020 RT-LAMP for rapid diagnosis
- 792 of coronavirus. *Microb. Biotechnol.* **3**, 950–961.
- 793 (doi:10.1111/1751-7915.13586)
- 794 92. Nassar JM, Khan SM, Velling SJ, Diaz-Gaxiola A,
- 795 Shaikh SF, Gerald NR, Torres Sevilla GA, Duarte CM,
- 796 Hussain MM. 2018 Compliant lightweight non-
- 797 invasive standalone 'Marine Skin' tagging system.
- 798 *Flex. Electron.* **2**, 13. (doi:10.1038/s41528-018-0025-1)